Last reviewed 2026-05-27 · How we verify

Buprenorphine patch and sublingual tablets

Psychiatric University Hospital, Zurich · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Buprenorphine patch and sublingual tablets is a Small molecule drug developed by Psychiatric University Hospital, Zurich. It is currently FDA-approved. Also known as: Transtec (buprenorphine patch), Subutex (buprenorphine sublingual tablets).

Buprenorphine patches and sublingual tablets are used to treat heroin addiction, as indicated by clinical trials on ClinicalTrials.gov. As a small molecule mu opioid receptor agonist, buprenorphine works by activating the mu-type opioid receptor, according to ChEMBL.

At a glance

Generic name	Buprenorphine patch and sublingual tablets
Also known as	Transtec (buprenorphine patch), Subutex (buprenorphine sublingual tablets)
Sponsor	Psychiatric University Hospital, Zurich
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Buprenorphine patch and sublingual tablets CI brief — competitive landscape report
Buprenorphine patch and sublingual tablets updates RSS · CI watch RSS
Psychiatric University Hospital, Zurich portfolio CI

Frequently asked questions about Buprenorphine patch and sublingual tablets

What is Buprenorphine patch and sublingual tablets?

Buprenorphine patch and sublingual tablets is a Small molecule drug developed by Psychiatric University Hospital, Zurich.

Who makes Buprenorphine patch and sublingual tablets?

Buprenorphine patch and sublingual tablets is developed and marketed by Psychiatric University Hospital, Zurich (see full Psychiatric University Hospital, Zurich pipeline at /company/psychiatric-university-hospital-zurich).

Is Buprenorphine patch and sublingual tablets also known as anything else?

Buprenorphine patch and sublingual tablets is also known as Transtec (buprenorphine patch), Subutex (buprenorphine sublingual tablets).

What development phase is Buprenorphine patch and sublingual tablets in?

Buprenorphine patch and sublingual tablets is FDA-approved (marketed).

Manufacturer: Psychiatric University Hospital, Zurich — full pipeline
Also known as: Transtec (buprenorphine patch), Subutex (buprenorphine sublingual tablets)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing